New perspectives on pharmacotherapy in the algorithm of colorectal cancer liver metastases management

Česká verzia

Authors: L. Petruželka ¹; M. Ryska ²; Z. Krška ³; M. Vočka ¹; P. Georgiev ¹; J. Pudil ²
Authors place of work: Onkologická klinika 1. LF UK a VFN – ÚVN Praha ¹; Chirurgická klinika 2. LF UK a ÚVN Praha ²; I. chirurgická klinika 1. LF UK a VFN Praha ³
Published in the journal: Gastroent Hepatol 2014; 68(5): 424-429
Category: Gastrointestinal Oncology: Review Article
doi: https://doi.org/10.14735/amgh2014424

Summary

Neoadjuvant systemic pharmacotherapy has the potential to convert initially unresectable metastases to resectable ones. The exact criteria for patient selection, optimum therapeutic regime and duration of neoadjuvant therapy, including the timing of surgical intervention, depend on many factors related to the patient (performance status, co-morbidities, etc.) and to the disease (extent and localization of metastases, synchronous vs metachronous form, etc.). The real conversion rate is likely to be low.

Key words:
colorectal cancer – liver metastases – treatment – conversion

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
29. 8. 2014

Accepted:
2. 10. 2014

Zdroje

1. Petruželka L. Kolorektální karcinom. In: Marek J (ed.). Farmakoterapie vnitřních nemocí. 4. ed. Praha: Grada 2010: 554–558.

2. Heinemann V, Douillard JY, Ducreux M et al. Targeted therapy in metastatic colorectal cancer – an example of personalised medicine in action. Cancer Treat Rev 2013; 39(6): 592–601. doi: 10.1016/j.ctrv.2012.12.011.

3. Stein A, Bokemeyer C. Prolonging survival through a personalized approach in metastatic colorectal cancer. J Oncopathology 2013; 1(3): 31–41. doi: 10.13032/tjop.2052-5931.100047.

4. Venook AP, Weiser MR, Tepper JE. Colorectal cancer: all hands on deck. ASCO University Educational Book 2014. [online]. Available from: http://meetinglibrary.asco.org/content/114000083-144.

5. Jain VK, Hawkes EA, Cunningham D. Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10(4): 245–257. doi: 10.1016/j.clcc.2011.04.001.

6. Venook AP, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum. ASCO Annual Meeting. LBA3 2014.

7. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23(10): 2479–2516.

8. Petruželka L, Vočka M, Georgiev P. Individualizace léčby nemocných s metastazujícím kolorektálním karcinomem – současný stav a výhledy. In: Kolorektální karcinom. Farmakoterapie 2013.

9. Grusenmeyer PA, Grubbs SS. Developing and implementing multidisciplinary disease-specific clinics in cancer care. Gastrointestinal (colorectal) cancer. ASCO Educational Book 2009.

10. Heinemann V, von Weikersthal LF, Decker T et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO Annual Meeting 2013: Abstr. LBA3506.

11. Oliner KS, Douillard JY, Sienna S et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer. ASCO Annual Meeting 2013: Abstr. 3511.

12. Morris EJ, Forman D, Thomas JD et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97(7): 1110–1118. doi: 10.1002/bjs.7032.

13. Petruželka L. Indikace indukční systémové léčby jaterních metastáz. Postgraduální medicína 2010; 3: 324–328.

14. Adam R, Wicherts DA, de Haas RJ et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27(11): 1829–1835. doi: 10.1200/JCO.2008.19.9273.

15. De Jong MC, Pulitano C, Ribero D et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250(3): 440–448. doi: 10.1097/SLA.0b013e3181b4539b.

16. Viganò L, Capussotti L, Lapointe R et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 2014; 21(4): 1276–1286. doi: 10.1245/s10434-013-3421-8.

17. Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17(10): 1225–1239. doi: 10.1634/theoncologist.2012-0121.

18. Petruželka L, Georgiev P. Přínos neoadjuvantní a adjuvantní léčby v léčbě kolorektálního karcinomu. Rozhl Chir 2012; 91(1): 53–58.

19. Ryska M, Pantoflíček J, Dušek L. Léčba jaterních metastáz kolorektálního původu v České republice: současný celostátní survey. Rozhl Chir 2010; 89(2): 100–108.

20. Primrose JN, Falk S, Finch-Jones M et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. J Clin Oncol 2013; 31 (Suppl): Abstr. 3504.

21. Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240(6): 1052–1061.

22. Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241(5): 715–722.

23. Blazer DG 3rd, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26(33): 5344–5351. doi: 10.1200/JCO.2008.17.5299.

24. Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29(8): 1083–1090. doi: 10.1200/JCO.2010.32.6132.

25. Are C, Gonen M, Zazzali K et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 2007; 246(2): 295–300.

26. Andreou A, Aloia TA, Brouquet A et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013; 257(6): 1079–1088. doi: 10.1097/SLA.0b013e318283a4d1.

27. Adam R, Wicherts DA, de Haas RJ et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26(10): 1635–1641. doi: 10.1200/JCO.2007.13.7471.

28. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24(24): 3939–3945.

29. Poultsides GA, Servais EL, Saltz LB et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27(20): 3379–3384. doi: 10.1200/JCO.2008.20.9817.

30. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12(1): 38–50.